The Relative Strength (RS) Rating for Aurinia Pharmaceuticals climbed into a new percentile Tuesday, with a rise from 79 to 82. Last week it actually hit 83, then fell on a couple of down days before reversing higher.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This unique rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against that of all other stocks.
Decades of market research reveals that the top-performing stocks tend to have an RS Rating of at least 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Aurinia Pharmaceuticals is still working on a consolidation with a 12.13 buy point. See if the stock can finally break out in heavy trade.
The company reported 0% earnings growth in its most recent report. Sales gains came in at 59%. The company is expected to report its latest earnings and sales numbers on or around Aug. 9.
Aurinia Pharmaceuticals holds the No. 20 rank among its peers in the Medical-Biomed/Biotech industry group. Arcturus Therapeutics and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
